J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
This article was originally published in The Tan Sheet
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
You may also be interested in...
Pfizer will appoint Wyeth's consumer health president to manage its new Diversified Businesses group, which will include consumer, nutritional and animal health, as part of a reorganization following the companies' planned merger
One option for Johnson & Johnson in response to Merck's bid for Schering-Plough is to make a deal for the latter's consumer health business
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal